Role of Transporters in Central Nervous System Drug Delivery and Blood-Brain Barrier Protection: Relevance to Treatment of Stroke
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Ischemic stroke is a leading cause of morbidity and mortality in the United States. The only approved pharmacologic treatment for ischemic stroke is thrombolysis via recombinant tissue plasminogen activator (r-tPA). A short therapeutic window and serious adverse events (ie, hemorrhage, excitotoxicity) greatly limit r-tPA therapy, which indicates an essential need to develop novel stroke treatment paradigms. Transporters expressed at the blood-brain barrier (BBB) provide a significant opportunity to advance stroke therapy via central nervous system delivery of drugs that have neuroprotective properties. Examples of such transporters include organic anion–transporting polypeptides (Oatps) and organic cation transporters (Octs). In addition, multidrug resistance proteins (Mrps) are transporter targets in brain microvascular endothelial cells that can be exploited to preserve BBB integrity in the setting of stroke. Here, we review current knowledge on stroke pharmacotherapy and demonstrate how endogenous BBB transporters can be targeted for improvement of ischemic stroke treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thresholds in cerebral ischemia - the ischemic penumbra.
Astrup, J., Siesjö, B. K., & Symon, L. (1981) · Stroke · doi:10.1161/01.str.12.6.723 · Cited by 2,820
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.-C., Moskowitz, M. A., Fini, M. E., & Lo, E. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07724.2001 · Cited by 1,004
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Blood–brain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke
Khatri, R., McKinney, A. M., Swenson, B., & Janardhan, V. (2012) · Neurology · doi:10.1212/wnl.0b013e3182697e70 · Cited by 478
Shawahna, R., Uchida, Y., Declèves, X., Ohtsuki, S., Yousif, S., Dauchy, S., Jacob, A., Chassoux, F., Daumas-Duport, C., Couraud, P.-O., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200129p · Cited by 372
Pathogenesis of Brain Edema and Investigation into Anti-Edema Drugs
Michinaga, S., & Koyama, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16059949 · Cited by 339
Lochhead, J. J., McCaffrey, G., Quigley, C. E., Finch, J., DeMarco, K. M., Nametz, N., & Davis, T. P. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.29 · Cited by 334
Ischemia-Reperfusion Injury in Stroke
Nour, M., Scalzo, F., & Liebeskind, D. S. (2012) · Interventional Neurology · doi:10.1159/000353125 · Cited by 316
Statins: Mechanisms of neuroprotection
van der Most, P. J., Dolga, A. M., Nijholt, I. M., Luiten, P. G. M., & Eisel, U. L. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.02.002 · Cited by 268
Huang, J., Agus, D. B., Winfree, C. J., Kiss, S., Mack, W. J., McTaggart, R. A., Choudhri, T. F., Kim, L. J., Mocco, J., Pinsky, D. J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171325998 · Cited by 225
Hirrlinger, J., König, J., Keppler, D., Lindenau, J., Schulz, J. B., & Dringen, R. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00101.x · Cited by 158
Lin, C., Tai, Y., Huang, M., Tsai, Y., Hsu, H., Tzen, K., & Liou, H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06801.x · Cited by 119
Involvement of oxidative stress in hypoxia-induced blood-brain barrier breakdown
Al Ahmad, A., Gassmann, M., & Ogunshola, O. O. (2012) · Microvascular Research · doi:10.1016/j.mvr.2012.05.008 · Cited by 81
Thompson, B. J., Sanchez-Covarrubias, L., Slosky, L. M., Zhang, Y., Laracuente, M.-L., & Ronaldson, P. T. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.4 · Cited by 72
Self-citation
Cited by
Abdullahi, W., Tripathi, D., & Ronaldson, P. T. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00095.2018 · Cited by 613
Self-citationRonaldson, P. T., & Davis, T. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20951995 · Cited by 392
“Treatment of the ischemic core is virtually impossible due to rapid development of necrosis; however, the penumbra is a primary target for therapeutic intervention due to slower cell degradation.(3,118,119) Recombinant tissue plasminogen activator (r-tPA, alteplase) is the only drug approved for clinical use as a stro…”
BackgroundSelf-citationApplications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Ceña, V., & Játiva, P. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0139 · Cited by 232
Communication pathways to and from the inner ear and their contributions to drug delivery
Salt, A. N., & Hirose, K. (2018) · Hearing Research · doi:10.1016/j.heares.2017.12.010 · Cited by 201
“Active transport across the blood-brain barrier involves many proteins in the solute carrier (SLC: 52 families, almost 400 genes) and ATP-binding cassette (ABC) families (Brzica et al., 2017), many of which may be similarly utilized in the blood-labyrinth barrier.”
Background
Metadata
- Authors
- Brzica, H., Abdullahi, W., Ibbotson, K., & Ronaldson, P. T.
- Venue
- Journal of Central Nervous System Disease
- Publisher
- SAGE Publications
- Published
- 2017-01-01
- Volume
- 9
- Pages
- 117957351769380
- ISSN
- 1179-5735 (ISSN-L)
- OpenAlex
- W2604766840
- Cited by
- 77
- References
- 17
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.